Article
Gastroenterology & Hepatology
Nikolas Plevris, James Fulforth, Spyros Siakavellas, Andrew Robertson, Rebecca Hall, Amy Tyler, Philip W. Jenkinson, Iona Campbell, Cher Shiong Chuah, Claire Kane, Jennifer Veryan, Wai Liam Lam, Jayne Saunders, Christopher Kelly, Daniel Gaya, Hasnain Jafferbhoy, Jonathan C. Macdonald, John Paul Seenan, Craig Mowat, Graham Naismith, Lindsay F. Potts, Diarmid Ian Sutherland, David Watts, Ian Arnott, Gillian Bain, Gareth Jones, Charlie W. Lees
Summary: The study aimed to evaluate the real-world effectiveness and safety of ustekinumab for treating Crohn's disease in patients in Scotland. Results showed that ustekinumab is a safe and effective treatment for complex Crohn's disease, with good rates of clinical remission, mucosal healing, and deep remission observed in the study.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
L. Monin, S. Dubois, C. Reenaers, C. Van Kemseke, P. Latour, D. Van Daele, S. Vieujean, L. Seidel, E. Louis
Summary: The study found that a large proportion of Crohn's disease patients responded well to ustekinumab initially and continued treatment beyond one year. Treatment persistence was similarly high in both patients who had previously failed other biologics and those who were bio-naive.
DIGESTIVE AND LIVER DISEASE
(2021)
Article
Gastroenterology & Hepatology
Rajat Garg, Manik Aggarwal, Robert Butler, Jean Paul Achkar, Bret Lashner, Jessica Philpott, Benjamin Cohen, Taha Qazi, Florian Rieder, Miguel Regueiro, Benjamin Click
Summary: UST is safe and effective in elderly CD patients, with similar outcomes as nonelderly patients. Age is not associated with clinical outcomes, while differences exist between elderly and nonelderly patients in Crohn's disease activity and prior biologic use. Real-world data in this IBD population can help inform biologic positioning.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Diego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollon, Jose Miguel Arbones-Mainar, Berta Caballol, Javier P. Gisbert, Montserrat Rivero, Eugenia Sanchez-Rodriguez, Lara Arias Garcia, Ana Gutierrez Casbas, Olga Merino, Lucia Marquez, Viviana Laredo, Maria Dolores Martin-Arranz, Pilar Lopez Serrano, Sabino Riestra Menendez, Carlos Gonzalez-Munoza, Luisa de Castro Parga, Marta Calvo Moya, Esteban Fuentes-Valenzuela, Maria Esteve, Marisa Iborra, Miguel Dura Gil, Manuel Barreiro-De Acosta, Rufo Humberto Lorente-Poyatos, Noemi Mancenido, Margalida Calafat, Iago Rodriguez-Lago, Jordi Guardiola Capo, Maria Antonia Payeras, Victor Jair Morales Alvarado, Carlos Tardillo, Luis Bujanda, Jose Fernando Munoz-Nunez, Yolanda Ber Nieto, Fernando Bermejo, Pedro Almela, Merce Navarro-Llavat, Pilar Martinez Montiel, Cristina Rodriguez Gutierrez, Manuel Van Domselaar, Eva Sese, Teresa Martinez Perez, Elena Ricart, Maria Chaparro, Maria Jose Garcia, Antonio Lopez-Sanroman, Beatriz Sicilia, Beatriz Orts, Alicia Lopez-Garcia, Eduardo Martin-Larraz, Jose Lazaro Perez-Calle, Ruth de Francisco, Esther Garcia-Planella, Eugeni Domenech, Santiago Garcia-Loper
Summary: Ustekinumab shows similar effectiveness in elderly patients with CD as it does in non-elderly patients. The safety profile is also similar, except for a higher rate of de novo neoplasms in elderly patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Maria Chaparro, Iria Baston-Rey, Estela Fernandez-Salgado, Javier Gonzalez Garcia, Laura Ramos, Maria Teresa Diz-Lois Palomares, Federico Arguelles-Arias, Eva Iglesias Flores, Mercedes Cabello, Saioa Rubio Iturria, Andrea Nunez Ortiz, Mara Charro, Daniel Ginard, Carmen Duenas Sadornil, Olga Merino Ochoa, David Busquets, Eduardo Iyo, Ana Gutierrez Casbas, Patricia Ramirez de la Piscina, Marta Maia Bosca-Watts, Maite Arroyo, Maria Jose Garcia, Esther Hinojosa, Jordi Gordillo, Pilar Martinez Montiel, Benito Velayos Jimenez, Cristina Quilez Ivorra, Juan Maria Vazquez Moron, Jose Maria Huguet, Yago Gonzalez-Lama, Ana Isabel Munagorri Santos, Victor Manuel Amo, Maria Dolores Martin-Arranz, Fernando Bermejo, Jesus Martinez Cadilla, Cristina Rubin de Celix, Paola Fradejas Salazar, Antonio Lopez San Roman, Nuria Jimenez, Santiago Garcia Lopez, Anna Figuerola, Itxaso Jimenez, Francisco Jose Martinez Cerezo, Carlos Taxonera, Pilar Varela, Ruth de Francisco, David Monfort, Gema Molina Arriero, Alejandro Hernandez Camba, Francisco Javier Garcia-Alonso, Manuel Van Domselaar, Ramon Pajares Villarroya, Alejandro Nunez, Francisco Rodriguez Moranta, Ignacio Marin-Jimenez, Virginia Robles Alonso, Maria del Mar Martin Rodriguez, Patricia Camo-Monterde, Ivan Garcia Tercero, Mercedes Navarro Llavat, Lara Arias Garcia, Daniel Hervias Cruz, Sara Sulleiro, Cynthia Novella, Eugenia Vispo, Manuel Barreiro-de Acosta, Javier P. Gisbert
Summary: This large retrospective study demonstrates the effectiveness and safety of ustekinumab as a short- and long-term treatment option for patients with Crohn's disease in real-world clinical practice, including those with refractory disease.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Qian Cao, Chunxiao Chen, Xiang Gao, Yan Chen, Naizhong Hu, Jie Liang, Kaichun Wu
Summary: Research shows that ustekinumab is more effective in treating Crohn's disease than anti-tumor necrosis factor treatment for patients who did not respond to previous treatment. The remission rates of ustekinumab are superior to those in the UNITI-1 study.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Rocio Sedano, Leonardo Guizzetti, Cassandra McDonald, Melanie Beaton, Nilesh Chande, Jamie Gregor, Michael Sey, Aze Wilson, Vipul Jairath
Summary: In this study, we observed high rates of clinical, endoscopic, radiological, and biochemical response and remission in patients with Crohn's Disease treated with ustekinumab, with greater effectiveness in bio-naive patients compared to bio-experienced patients.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Anders Forss, Mark Clements, Par Myrelid, Hans Strid, Charlotte Soderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson
Summary: This study demonstrates the long-term clinical effectiveness of ustekinumab in patients with active Crohn's disease, as well as its improvement in Health-related Quality of Life (HRQoL) measures.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Jacob E. Ollech, Inessa Normatov, Noam Peleg, Jingzhou Wang, Shivani A. Patel, Victoria Rai, Yangtian Yi, Jorie Singer, Sushila R. Dalal, Atsushi Sakuraba, Russell D. Cohen, David T. Rubin, Joel Pekow
Summary: Shortening the ustekinumab dose interval to 4 weeks improved clinical and biological indices of disease activity in patients with Crohn's disease who did not respond to the standard dose every 8 weeks. This approach could be effective and safe for patients who lose response to the standard dose of ustekinumab.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Pepijn W. A. Thomas, Mark van Caem, Rachel L. West, Maurice G. V. M. Russel, Jeroen M. Jansen, Tessa E. H. Romkens, Frank Hoentjen
Summary: This study aimed to evaluate the effectiveness and safety of ustekinumab in treating Crohn's disease beyond 52 weeks. The results showed that more than half of the patients continued using ustekinumab after 104 weeks and one-third achieved corticosteroid-free clinical remission.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Frank I. Scott, Amneet K. Hans, Mark E. Gerich, Blair Fennimore, Ronac Mamtani, Ravy K. Vajravelu, James D. Lewis
Summary: In simulation study, ustekinumab as the first-line biologic therapy for a 35-year-old male patient with moderate to severe CD yielded greater QALYs at the end of 1 year compared with its use later in the CD treatment algorithm.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Jiayin Yao, Heng Zhang, Tao Su, Xiang Peng, Junzhang Zhao, Tao Liu, Wei Wang, Pinjin Hu, Min Zhi, Min Zhang
Summary: There is insufficient evidence to confirm the efficacy of ustekinumab (UST) in promoting fistula closure in perianal fistulizing Crohn's disease (CD) patients. However, a real-world study found that UST can promote fistula closure and the efficacy is correlated with increased UST trough concentration.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Cristina Rubin de Celix, Maria Chaparro, Javier P. Gisbert
Summary: The study found that ustekinumab had good effectiveness and safety in Crohn's disease patients, but 18% of patients lost response during follow-up. Nearly one-third of the patients needed dose optimization, and it was effective in most cases.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Amanda M. Johnson, Maria Barsky, Waseem Ahmed, Samantha Zullow, Jonathan Galati, Vipul Jairath, Neeraj Narula, Farhad Peerani, Benjamin H. Click, Elliot S. Coburn, ThucNhi Tran Dang, Stephanie Gold, Manasi Agrawal, Rajat Garg, Manik Aggarwal, Danah Mohammad, Brendan Halloran, Gursimran S. Kochhar, Hannah Todorowski, Nabeeha Mohy Ud Din, James Izanec, Amanda Teeple, Chris Gasink, Erik Muser, Zhijie Ding, Arun Swaminath, Komal Lakhani, Dan Hogan, Samit Datta, Ryan C. Ungaro, Brigid S. Boland, Matthew Bohm, Monika Fischer, Sashidhar Sagi, Anita Afzali, Thomas Ullman, Garrett Lawlor, Daniel C. Baumgart, Shannon Chang, David Hudesman, Dana Lukin, Ellen J. Scherl, Jean-Frederic Colombel, Bruce E. Sands, Corey A. Siegel, Miguel Regueiro, William J. Sandborn, David Bruining, Sunanda Kane, Edward V. Loftus, Parambir S. Dulai
Summary: This study evaluated the real-world effectiveness and safety of ustekinumab in patients with Crohn's disease. The results demonstrated that ustekinumab is a safe and effective treatment option for Crohn's disease, especially for biologic-naive patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Maria Lia Scribano, Annalisa Aratari, Benedetto Neri, Cristina Bezzio, Paola Balestrieri, Valentina Baccolini, Giuliano Falasco, Caterina Camastra, Paolo Pantanella, Rita Monterubbianesi, Alessandro Tullio, Simone Saibeni, Claudio Papi, Livia Biancone, Rocco Cosintino, Roberto Faggiani
Summary: This study assessed the effectiveness of ustekinumab in a large cohort of Italian patients with refractory Crohn's disease. The results showed that ustekinumab can achieve corticosteroid-free clinical remission in most patients, with significant decreases in HBI and CRP values. The normalization rate of CRP values also increased over time.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
William J. Sandborn, Julian Panes, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F. Valentine, David Laharie, Carolina Baia, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Severine Vermeire
Summary: This study compared the safety and efficacy of two doses of Etrolizumab with placebo in patients with Crohn's disease. The results showed that during the maintenance phase, Etrolizumab significantly improved clinical remission and endoscopic improvement in patients with moderately to severely active Crohn's disease compared to placebo. However, there was no significant difference in the effects of Etrolizumab and placebo on clinical remission and endoscopic improvement during the induction phase.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Dotan Yogev, Bram Verstockt, Axel Dignass, Gili Focht, Ohad Atia, Iris Dotan, Severine Vermeire, Dan Turner
Summary: Evaluation of the modified version of the Mucosal Inflammation Noninvasive Index in adult Crohn's disease.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Gary R. Lichtenstein, Brian Bressler, Carlos Francisconi, Severine Vermeire, Nervin Lawendy, Leonardo Salese, Gosford Sawyerr, Hongjiong Shi, Chinyu Su, Donna T. Judd, Thomas Jones, Edward V. Loftus
Summary: Age is considered a risk factor for adverse events in the tofacitinib ulcerative colitis clinical program, with older individuals potentially having a higher risk of herpes zoster, malignancies (excluding nonmelanoma skin cancer), and nonmelanoma skin cancer compared to younger patients.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Gastroenterology & Hepatology
Nurulamin M. Noor, Paula Sousa, Dominik Bettenworth, Fernando Gomollon, Triana Lobaton, Peter Bossuyt, Maria Jose Casanova, Nik S. Ding, Gabriele Dragoni, Federica Furfaro, Patrick F. van Rheenen, Maria Chaparro, Javier P. Gisbert, Edouard Louis, Konstantinos Papamichael
Summary: There is an increasing interest in discontinuing biological treatment for patients with Crohn's disease after a sustained period of remission. Evidence to date suggests that re-treatment with the same biological agent can often regain remission in cases of relapse. The concept of cycling biological therapy may allow a lower therapeutic burden for a subgroup of patients, ensuring disease control with decreased exposure to biological therapy.
JOURNAL OF CROHNS & COLITIS
(2023)
Letter
Gastroenterology & Hepatology
Dahham Alsoud, Jessica Ho, Bram Verstockt
JOURNAL OF CROHNS & COLITIS
(2023)
Editorial Material
Gastroenterology & Hepatology
Markus Tschurtschenthaler, Bram Verstockt
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Gabriele Bislenghi, Julie Van Den Bossch, Steffen Fieuws, Albert Wolthuis, Marc Ferrante, Gert de Hertogh, Severine Vermeire, Andre D'Hoore
Summary: The macroscopic appearance of the bowel and associated mesentery during surgery does not appear to be predictive of postoperative recurrence after ileocecal resection for Crohn's disease. Prospective studies investigating risk factors for Crohn's disease recurrence after surgery are scarce.
INFLAMMATORY BOWEL DISEASES
(2023)
Meeting Abstract
Gastroenterology & Hepatology
L. Fierens, P. Bossuyt, F. Baert, D. Baert, M. Lavaerts, C. Weltens, M. Ferrante
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
J. Hanzel, F. Baert, M. Lowenberg, M. Ferrante, P. Bossuyt, F. Hoentjen, D. Franchimont, K. Palatka, H. Peeters, A. Mookhoek, G. de Hertogh, E. Clasquin, S. Vermeire, G. D'Haens
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Lenfant, S. Vermeire, J. Sabino, M. Ferrante, B. Verstockt, G. De Hertogh
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
E. Melon-Ardanaz, M. Veny, A. M. Corraliza, A. Garrido-Trigo, M. Esteller, M. Rodrigo, B. Verstockt, S. Vermeire, M. C. Masamunt, A. Giner, I. Ordas, A. Fernandez-Clotet, E. Ricart, J. Panes, A. Salas
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Severine Vermeire, Geert D'Haens, Julian Panes, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravata, Frederic Lavie, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Loewenberg, Daniel R. Gaya, Silvio Danese
Summary: The STARDUST LTE study is the first interventional study to investigate the efficacy of ustekinumab in Crohn's disease. The study showed that flexible, algorithm-driven dose adjustment, including dose reduction, preserved clinical and endoscopic outcomes for up to 104 weeks.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Severine Vermeire, Jurij Hanzel, Mark Lowenberg, Marc Ferrante, Peter Bossuyt, Frank Hoentjen, Denis Franchimont, Karoly Palatka, Harald Peeters, Aart Mookhoek, Gert de Hertogh, Tamas Molnar, Wouter van Moerkercke, Triana Lobaton, Esme Clasquin, Melanie S. Hulshoff, Filip Baert, Geert D'Haens
Summary: This study explored the differential efficacy of vedolizumab in early and late ulcerative colitis and evaluated clinical, endoscopic, and histological outcomes. The results showed no significant differences between early and late UC in terms of clinical, endoscopic, and histological improvement.
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Inge Jacobs, Bo-Jun Ke, Jonathan Cremer, Andre D'Hoore, Gabriele Bislenghi, Gianluca Matteoli, Gert De Hertogh, Joao Sabino, Marc Ferrante, Severine Vermeire, Christine M. Breynaert, Tim Vanuytsel, Bram Verstockt
Meeting Abstract
Gastroenterology & Hepatology
Bep Keersmaekers, Matthias Lenfant, Ilse van den Eijnden, Anouk Teugels, Joao Sabino, Bram Verstockt, Severine Vermeire, Ilse Van Diest, Marc Ferrante